Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Shares Outstanding (Weighted Average) (2023 - 2026)

Camp4 Therapeutics' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $142.0 for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 100.0% to $142.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $142.0, a 100.0% decrease, with the full-year FY2025 number at $142.0, down 100.0% from a year prior.
  • Shares Outstanding (Weighted Average) hit $142.0 in Q4 2025 for Camp4 Therapeutics, down from $22.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CAMP hit a ceiling of $22.6 million in Q3 2025 and a floor of $142.0 in Q4 2025.
  • Historically, Shares Outstanding (Weighted Average) has averaged $7.0 million across 3 years, with a median of $493547.5 in 2024.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 4379.93% in 2025, down 100.0% in 2025.
  • Tracing CAMP's Shares Outstanding (Weighted Average) over 3 years: stood at $394976.0 in 2023, then skyrocketed by 1087.44% to $4.7 million in 2024, then crashed by 100.0% to $142.0 in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CAMP at $142.0 in Q4 2025, $22.6 million in Q3 2025, and $20.2 million in Q2 2025.